The world's first dengue vaccine CYD-TDV has passed the crucial India test and could be available in the country as early as by the end of next year.
In an exclusive interview to TOI, the vaccine makers Sanofi Pasteur revealed that their first study of the vaccine on Indian adults (aged 18-45 years) across five sites in India — Delhi, Ludhiana, Bangalore, Pune and Kolkata found the vaccine "safe and immunogenic in Indian adults" with results comparable to other clinical studies in Asia.
In an exclusive interview to TOI, the vaccine makers Sanofi Pasteur revealed that their first study of the vaccine on Indian adults (aged 18-45 years) across five sites in India — Delhi, Ludhiana, Bangalore, Pune and Kolkata found the vaccine "safe and immunogenic in Indian adults" with results comparable to other clinical studies in Asia.
No comments:
Post a Comment